SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-24-122191
Filing Date
2024-04-29
Accepted
2024-04-29 16:01:59
Documents
15
Period of Report
2024-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A d636298ddef14a.htm DEF 14A 659952
2 GRAPHIC g636298g00a02.jpg GRAPHIC 21136
3 GRAPHIC g636298g00a03.jpg GRAPHIC 20953
4 GRAPHIC g636298g01g01.jpg GRAPHIC 280735
5 GRAPHIC g636298g02g02.jpg GRAPHIC 184378
6 GRAPHIC g636298g11i11.jpg GRAPHIC 26057
7 GRAPHIC g636298g22i22.jpg GRAPHIC 26232
8 GRAPHIC g636298g24q24.jpg GRAPHIC 131536
9 GRAPHIC g636298g33i33.jpg GRAPHIC 25624
10 GRAPHIC g636298g35z31.jpg GRAPHIC 24028
11 GRAPHIC g636298g42r42.jpg GRAPHIC 127407
12 GRAPHIC g636298g44i44.jpg GRAPHIC 24536
13 GRAPHIC g636298g49q08.jpg GRAPHIC 107122
14 GRAPHIC g636298g57t78.jpg GRAPHIC 51485
15 GRAPHIC g636298g69o10.jpg GRAPHIC 38750
  Complete submission text file 0001193125-24-122191.txt   2137000
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36510 | Film No.: 24890485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)